| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Director | Chief Operating Officer
3 companies
Neil F. McFarlane is President and CEO at ZVRA, with reported holdings spanning 3 companies. Neil F. McFarlane's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.8M at current prices.
Our model assigns Neil F. McFarlane a below-average insider score of 34/100, based on 5 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -5.1%.
Neil F. McFarlane's largest disclosed position is in ZVRA as President and CEO, worth about $4.3M. The ZVRA filings lean toward selling, a net 236,942 shares.
Neil F. McFarlane has 23 Form 4 filings on record from August 2016 to October 2026, across 3 companies: President and CEO at Zevra Therapeutics (ZVRA), 2023–2026; Director at Collegium Pharmaceutical (COLL), 2022–2024; Chief Operating Officer at Travere Therapeutics (TVTX), 2016–2019.
The 38 reported transactions were 13 open-market sales, 11 option or other derivative awards, 9 stock awards and 5 option exercises.
Counted by filing, the open-market trades come to no purchases and 9 sales worth about $2.7M.
The largest open-market sale was 91,000 shares of ZVRA at an average $9.38 on February 2, 2026, about $853K.
All 5 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | ZVRA Zevra Therapeutics, Inc. | President and CEO | Sale+OE10b5-1 | 20,000 | $11.25 | $224,948.00 | -4.6% | - | - | |
| Feb 9, 2026 | ZVRA Zevra Therapeutics, Inc. | President and CEO | Sale+OE10b5-1 | 14,625 | $8.56 | $125,185.61 | -3.6% | +26.0% | - | |
| Feb 2, 2026 | ZVRA Zevra Therapeutics, Inc. | President and CEO | Sale+OE10b5-1 | 91,000 | $9.38 | $853,425.30 | -20.0% | +7.4% | - | |
| Oct 10, 2025 | ZVRA Zevra Therapeutics, Inc. | President and CEO | Sale+OE10b5-1 | 19,500 | $10.82 | $210,908.10 | -8.1% | -21.6% | +3.5% | |
| Feb 14, 2025 | ZVRA Zevra Therapeutics, Inc. | President and CEO | Sell10b5-1 | 91,817 | $7.92 | $727,389.76 | -32.4% | +4.5% | +5.3% | |
| May 16, 2019 | TVTX Travere Therapeutics, Inc. | Chief Operating Officer | Sell | 1,968 | $18.25 | $35,906.16 | -6.8% | - | - | |
| Dec 20, 2018 | TVTX Travere Therapeutics, Inc. | Chief Operating Officer | Sell | 11,125 | $22.32 | $248,333.18 | -27.8% | - | - | |
| Nov 14, 2018 | TVTX Travere Therapeutics, Inc. | Chief Operating Officer | Sell | 10,000 | $23.73 | $237,314.40 | -26.0% | - | - | |
| Aug 16, 2017 | TVTX Travere Therapeutics, Inc. | Chief Operating Officer | Sell | 1,378 | $22.50 | $31,005.00 | -9.2% | - | - |